Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications

International Clinical Psychopharmacology

Volumn 27, Issue 5, 2012, Pages 275-282

  Novick, Diego ^a,e   Haro, Josep Maria ^f   Bertsch, Jordan ^f   Anand, Hemant ^a   Jemiai, Nadia ^b   Haddad, Peter M ^c,d  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly ACE Neuroscience Medical Affairs ^*

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

antipsychotic; hospitalization; nonadherence; schizophrenia; treatment discontinuation

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG COST; DRUG FORMULATION; DRUG WITHDRAWAL; EUROPE; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; OBSERVATIONAL STUDY; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; SCHIZOPHRENIA; SYMPTOM;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; EUROPEAN UNION; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84864652814     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328354db12     Document Type: Article

References (42)

1. Adams CE, Fenton MKP, Quraishi S, David AS (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290-299. (Pubitemid 32996037)
2. American Psychiatric Association (2004). Practice guidelines for the treatment of patients with schizophrenia (2nd edition). Am J Psychiatry 161 (Suppl 2): 1-56.
3. Ascher-Svanum H, Peng X, Faries D, Montgomery W, Haddad PM (2009). Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry 9:2-9.
4. Awad AG, Voruganti LN (2008). The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 26:149-162.
5. Burns T (2007). Hospitalisation as an outcome measure in schizophrenia. Br J Psychiatry 191 (Suppl 50):37-41.
6. Ciudad A, Haro JM, Alonso J, Bousoño M, Suárez D, Novick D, et al. (2008). The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry 23:1-7. (Pubitemid 351221254)
7. Cramer JA, Rosenheck R (1998). Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196-201. (Pubitemid 28071427)
8. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108. (Pubitemid 41070734)
9. Dolder CR, Lacro JP, Jeste DV (2003). Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 65:156-162. (Pubitemid 36143209)
10. Guy G (1976). Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology (revised). Rockville, Maryland: National Institute of Mental Health.
11. Haddad PM, Taylor M, Niaz OS (2009). First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trails and observational studies. Br J Psychiatry 195:s20-s28.
12. Hamer S, Haddad PM (2007). Adverse effects of antipsychotics as outcome measures. Br J Psychiatry Suppl 50:s64-s70. (Pubitemid 47204558)
13. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al. (2003a). The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr Scand 107:222-232. (Pubitemid 36250283)
14. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. (2003b). The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 107 (Suppl 416):16-23.
15. Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M, et al. (2006a). Remission and relapse in the outpatient care of schizophrenia. Three-year results from the Schizophrenia Outpatient Health Outcomes Study. J Clin Psychopharmacol 26:571-578. (Pubitemid 44772733)
16. Haro JM, Novick D, Belger M, Jones PB (2006b). Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry 21:41-47. (Pubitemid 43243051)
17. Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D,Windmeijer F (2006c). Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy 5:11-25. (Pubitemid 43927196)
18. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, et al. (2007). Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17:235-244. (Pubitemid 46164772)
19. Haro JM, Novick D, Suarez D, Roca M (2009). Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res 43:265-273.
20. Johnson DAW (2009). Historical perspective on antipsychotic long-acting injections. Br J Psychiatry 195 (Suppl 52):7-12.
21. Law MR, Soumerai SB, Ross-Degnan D, Adams AS (2008). A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 69:47-53. (Pubitemid 351281996)
22. Leong OK, Wong KE, Tay WK, Gill RC (1989). A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Med J 30:436-440. (Pubitemid 20021364)
23. Leucht S, Heres S (2006). Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 (Suppl 5):3-8. (Pubitemid 43837695)
24. Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, et al. (1980). Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Adv Biochem Psychopharmacol 24:483-493.
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223. (Pubitemid 41345943)
26. Marcus SC, Olfson M (2008). Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 34:173-180. (Pubitemid 350262282)
27. Masand PS, Roca M, Turner MS, Kane JM (2009). Partial adherence to antipsychotic medication impacts course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 11:147-154.
28. McCreadie R, Mackie M, Morrison D, Kidd J (1982). Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 140:280-286. (Pubitemid 12184532)
29. Meuser KT, McGurk SR (2004). Schizophrenia. Lancet 363:2063-2072. (Pubitemid 38781110)
30. National Institute for Health and Clinical Excellence (NICE) (2009). Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 82 (update). London: NICE.
31. NoséM, Barbui C, Gray R, Tansella M (2003). Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 183:197-206. (Pubitemid 37070173)
32. Novick D, Haro JM, Perrin E, Suarez D, Texeira JM (2009a). Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol 19:542-550.
33. Novick D, Haro JM, Suarez D, Vieta E, Naber D (2009b). Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 108:223-230.
34. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM (2010). Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatr Res 176:109-113.
35. Oehl M, Hummer M, Fleischhacker WW (2000). Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 407:83-86. (Pubitemid 32115754)
36. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. (2009). Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24:287-296.
37. Sun SX, Liu GG, Christensen DB, Fu AZ (2007). Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 23:2305-2312. (Pubitemid 350033432)
38. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC (2003). Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 29:33-43. (Pubitemid 36871055)
39. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333:224-229.
40. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603-609.
41. Walker CA (1983). A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients. Pharmatherapeutica 3:289-293. (Pubitemid 13153457)
42. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR (2008). Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 59:315-317.